These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 1376910

  • 1. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR, Radulovic S, Groot K, Schally AV.
    Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J, Halmos G, Szepeshazi K, Schally AV.
    Cancer; 1993 Dec 01; 72(11):3263-70. PubMed ID: 8242552
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
    Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Cai RZ, Groot K, Vadillo-Buenfil M, Schally AV.
    Eur J Cancer; 1997 Jun 01; 33(7):1141-8. PubMed ID: 9376196
    [Abstract] [Full Text] [Related]

  • 6. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai RZ, Groot K, Schally AV.
    Prostate; 1997 Aug 01; 32(3):164-72. PubMed ID: 9254895
    [Abstract] [Full Text] [Related]

  • 7. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
    Yano T, Pinski J, Szepeshazi K, Halmos G, Radulovic S, Groot K, Schally AV.
    Cancer; 1994 Feb 15; 73(4):1229-38. PubMed ID: 8313327
    [Abstract] [Full Text] [Related]

  • 8. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW, Schally AV, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs JT.
    Cancer Res; 1992 May 01; 52(9):2538-44. PubMed ID: 1568223
    [Abstract] [Full Text] [Related]

  • 9. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice.
    Pinski J, Schally AV, Halmos G, Szepeshazi K.
    Int J Cancer; 1993 Dec 02; 55(6):963-7. PubMed ID: 7902829
    [Abstract] [Full Text] [Related]

  • 10. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K, O'Byrne K, Cai RZ.
    Br J Cancer; 1994 Nov 02; 70(5):886-92. PubMed ID: 7947094
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
    Szepeshazi K, Milovanovic S, Lapis K, Groot K, Schally AV.
    Breast Cancer Res Treat; 1992 Nov 02; 21(3):181-92. PubMed ID: 1355375
    [Abstract] [Full Text] [Related]

  • 13. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
    Srkalovic G, Szende B, Redding TW, Groot K, Schally AV.
    Proc Soc Exp Biol Med; 1989 Dec 02; 192(3):209-18. PubMed ID: 2574866
    [Abstract] [Full Text] [Related]

  • 14. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.
    Yano T, Pinski J, Szepeshazi K, Milovanovic SR, Groot K, Schally AV.
    Prostate; 1992 Dec 02; 20(4):297-310. PubMed ID: 1351672
    [Abstract] [Full Text] [Related]

  • 15. Combination treatment of nitrosamine-induced pancreatic cancers in hamsters with analogs of LH-RH and a bombesin/GRP antagonist.
    Szepshazi K, Halmos G, Groot K, Schally AV.
    Int J Pancreatol; 1994 Dec 02; 16(2-3):141-9. PubMed ID: 7868940
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II.
    Jungwirth A, Schally AV, Halmos G, Groot K, Szepeshazi K, Pinski J, Armatis P.
    Cancer; 1998 Mar 01; 82(5):909-17. PubMed ID: 9486581
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J, Reile H, Halmos G, Groot K, Schally AV.
    Cancer Res; 1994 Jan 01; 54(1):169-74. PubMed ID: 7903203
    [Abstract] [Full Text] [Related]

  • 18. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice.
    Pinski J, Halmos G, Schally AV.
    Cancer Lett; 1993 Jul 30; 71(1-3):189-96. PubMed ID: 8103419
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095).
    Radulovic S, Miller G, Schally AV.
    Cancer Res; 1991 Nov 01; 51(21):6006-9. PubMed ID: 1682040
    [Abstract] [Full Text] [Related]

  • 20. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors.
    Lee MT, Liebow C, Kamer AR, Schally AV.
    Proc Natl Acad Sci U S A; 1991 Mar 01; 88(5):1656-60. PubMed ID: 1672042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.